Form 4: Xeris Biopharma CLO Reports Stock Transactions

Xeris Biopharma's Chief Legal Officer, Beth Hecht, reported the acquisition of restricted stock units and stock options, alongside sales and tax-related dispositions of common stock.

Summary

• Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc., reported several transactions involving the company's common stock and derivative securities.
• On January 30, 2026, Hecht acquired 121,293 shares of common stock through a restricted stock unit (RSU) grant under the Company's 2018 Stock Option and Incentive Plan. These RSUs vest in equal annual installments over three years, contingent on continued employment.
• Also on January 30, 2026, Hecht acquired 162,162 stock options under the same plan, with an exercise price of $7.36. These options also vest in equal annual installments over three years, subject to continued service.
• On January 31, 2026, a total of 169,555 shares of common stock (98,375, 46,914, and 24,266 shares) were withheld by the Issuer to satisfy income tax and withholding obligations related to the net settlement of vested restricted stock units.
• On February 2, 2026, Hecht disposed of 16,667 shares of common stock at a weighted average price of $7.4487, with individual sales ranging from $7.250 to $7.590. This transaction was executed pursuant to a Rule 10b5-1 trading plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing. The grants of equity compensation are positive for executive alignment, while the sales are routine and expected under a 10b5-1 plan, not indicating a negative outlook.

Positives

• The grant of 121,293 restricted stock units and 162,162 stock options to a key executive like the Chief Legal Officer aligns management's interests with long-term shareholder value.
• The vesting schedule over three years for both RSUs and stock options encourages continued employment and service, promoting stability in leadership.

Negatives

• The sale of 16,667 shares of common stock by a key executive, even under a 10b5-1 plan, represents a reduction in direct ownership.
• A significant number of shares (169,555) were withheld for tax obligations, which, while standard for RSU vesting, reduces the executive's net share accumulation from the grants.

Future Outlook

The restricted stock units and stock options granted to Beth Hecht are subject to a three-year vesting schedule, requiring continued employment or service through the vesting dates. The stock options have an expiration date of January 30, 2036.

Industry Context

StockSavvy.ai notes that executive compensation packages in the biopharma industry frequently include equity components like restricted stock units and stock options to attract and retain talent, aligning executive incentives with company performance and long-term growth. The use of 10b5-1 plans for stock sales is a common practice among executives to manage personal finances while avoiding accusations of insider trading.

Comparison to Industry Standards

• The structure of equity compensation, including RSUs and stock options with multi-year vesting, is consistent with common practices in the biopharmaceutical sector for executive incentives.
• The use of a Rule 10b5-1 trading plan for stock sales is a standard compliance measure for corporate insiders, similar to practices observed at companies like Pfizer, Johnson & Johnson, and Moderna, ensuring pre-scheduled transactions and mitigating potential insider trading concerns.

Stakeholder Impact

• Shareholders: The equity grants align executive interests with shareholder value, while the 10b5-1 sale is a routine event with minimal direct impact on company operations or strategy.
• Employees: The vesting schedules for equity compensation reinforce the importance of continued service and employment for key executives.

Next Steps

• The acquired restricted stock units will vest in equal annual installments over three years, subject to continued employment.
• The acquired stock options will vest in equal annual installments over three years, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions, including equity compensation grants and a pre-scheduled sale under a 10b5-1 plan. Such transactions are common and generally do not indicate a significant change in the company's fundamental outlook or warrant a change in investment recommendation. The grants align executive incentives, while the sales are for personal financial management, not a signal of lack of confidence.

Keywords

Xeris Biopharma, XERS, Form 4, Insider Trading, Restricted Stock Units, Stock Options, 10b5-1 Plan, Executive Compensation, Common Stock, Biopharma